[Preliminary trials of immune function of erythrocytes in women with benign or malignant gynecologic tumors].
The immune function of erythrocytes in 74 women with benign or malignant gynecologic tumors were studied by red-cell immune adherence (RCIA), regulating factor of erythrocytes (RFER), inhibiting factor of erythrocytes (RFIR), and factor of promoting neutrocyte of erythrocytes (ERPN). Our results indicated that RCIA, RFER, and ERPN in women with malignant tumors were lower than those of normal and with benign tumors (P < 0.001). The RFIR of women with malignant tumors was higher than others (P < 0.001). Meanwhile, the changes of immune function of erythrocytes during treatment were compared and discussed. Our data suggested that women with malignant gynecologic tumors had lower immune function of erythrocytes.
Zhang
G N
GN
Sichuan Cancer Hospital, Chengdu.
D000328:Adult; D016889:Endometrial Neoplasms / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007104:Immune Adherence Reaction; D007889:Leiomyoma / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology*; D017463:Receptors, Complement 3b / Q000276:immunology; D002583:Uterine Cervical Neoplasms / Q000276:immunology*; D014594:Uterine Neoplasms / Q000276:immunology
D017463:Receptors, Complement 3b